4 Ways to Play the Boom in Biotech Stocks

This burgeoning sector holds plenty of promise, but how you play greatly depends on how much risk you can stomach

      View All  

Biotech Stocks: Gilead Sciences (GILD)

Gilead185 4 Ways to Play the Boom in Biotech StocksType: Large-cap stock
Market Cap: $113 billion

Gilead Sciences (GILD) built its reputation on its HIV drug franchise, racking up some $9 billion in sales for drugs like the four-in-one Stribild, as well as Truvada. The company also is successfully expanding beyond its core HIV drug portfolio into Hepatitis C with Sovaldi and Idelalisib, which combats non-Hodgkin’s lymphoma. The orally administered Sovaldi, with its reported cure rates near 90% in clinical trials, has the potential to be a blockbuster drug for GILD.

A couple of headwinds have emerged recently, however: Idenix Pharmaceuticals (IDIX) filed a patent infringement lawsuit against Gilead over Sovaldi; insurers — particularly those that administer Medicaid — are crying foul at Sovaldi’s hefty price tag: $84,000 for a 12-week course of the drug. Unlike many biopharmaceutical treatments that are geared toward rare conditions, the Hepatitis C market is huge globally, raising the possibility that Sovaldi could be one of the most profitable new drug launches in history.

The Takeaway: Although GILD shares have soared 70% in the past year, it’s still trading at just 14 times forward earnings and a price/earnings-to-growth ratio of 0.55, indicating it’s still undervalued. Better still, at a beta of 0.9, it’s less volatile than your typical biotech. If you’re looking for a large cap value stock in the biotech sector that combines size and relative stability with growth, there could be a place for GILD in your portfolio.


Article printed from InvestorPlace Media, http://investorplace.com/2014/03/biotech-stocks/.

©2015 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.